We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Cardinal (CAH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.95 per share, reflecting an increase of 12.1% compared to the same period last year. Revenues are forecasted to be $55.82 billion, representing a year-over-year increase of 10.6%.
The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenue- Pharmaceutical' will reach $51.89 billion. The estimate indicates a year-over-year change of +10.9%.
The combined assessment of analysts suggests that 'Revenue- Medical' will likely reach $3.61 billion. The estimate indicates a year-over-year change of -1.9%.
According to the collective judgment of analysts, 'Segment profit- Medical' should come in at $103.19 million. Compared to the current estimate, the company reported $20 million in the same quarter of the previous year.
Analysts forecast 'Segment profit- Pharmaceutical' to reach $606.65 million. Compared to the present estimate, the company reported $600 million in the same quarter last year.
Over the past month, shares of Cardinal have returned -7.8% versus the Zacks S&P 500 composite's -2% change. Currently, CAH carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Cardinal (CAH) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Cardinal Health (CAH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.95 per share, reflecting an increase of 12.1% compared to the same period last year. Revenues are forecasted to be $55.82 billion, representing a year-over-year increase of 10.6%.
The current level reflects a downward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Cardinal metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Revenue- Pharmaceutical' will reach $51.89 billion. The estimate indicates a year-over-year change of +10.9%.
The combined assessment of analysts suggests that 'Revenue- Medical' will likely reach $3.61 billion. The estimate indicates a year-over-year change of -1.9%.
According to the collective judgment of analysts, 'Segment profit- Medical' should come in at $103.19 million. Compared to the current estimate, the company reported $20 million in the same quarter of the previous year.
Analysts forecast 'Segment profit- Pharmaceutical' to reach $606.65 million. Compared to the present estimate, the company reported $600 million in the same quarter last year.
View all Key Company Metrics for Cardinal here>>>
Over the past month, shares of Cardinal have returned -7.8% versus the Zacks S&P 500 composite's -2% change. Currently, CAH carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>